GOVX · GeoVax Labs, Inc.
$0.19
-0.01 (-6.84%)
At close · Oct 26
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jul 27, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors collectively raise substantial doubt about the Company’s ability to continue as a going concern. Management believes that we will be successful in securing the additional capital required to continue the Company’s planned operations, but that our plans do not fully alleviate the substantial doubt about the Company’s ability to operate as a going concern.”View the 10-Q filed Jul 27, 2026
Market Cap
$1.52M
Shares
7.37M
Volume · Oct 26
204.5K
Avg daily vol (3M)
765.67K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.21
Open$0.23
Day$0.20–0.23
52W close$0.21–14.98
Avg vol 30d698K
Short int282K · 3.8% float · 1.2d
Short vol30%
Last earningsNov 13, 2025
DataSep 2020–Oct 2026
Filing10-Q · Jul 27
Up next
filed Jul 27, 2026
call held Nov 13, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$20.43M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1,210.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$3.14M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+710.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
3.8%
Latest settlement · 1.2 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 19.5 · elevated
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−85%
below
Price vs 50-day avg
−52%
below
RSI (14)
19
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−41%
trailing
6-month return
−84%
trailing
YTD return
−95%
this year
Relative strength
−90%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
2 of 17 funds reported for Sep 30 · net +521 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.82% of float · ▼ -43.5% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Squeeze score
45
elevated · 0–100
Fundamentals
Revenue growth
−37%
Y/Y
Free cash flow
$-21.5M
Balance sheet
$3.1M
net cash
Quant / Vol
risk profile
Volatility
140%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
16.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−85%
Bearish
Price vs 50-day avg
−52%
Bearish
RSI (14)
19
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
2 of 17 funds reported for Sep 30 · net +521 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.82% of float · ▼ -43.5% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $15
vs 200-day avg -85%
vs 50-day avg -52%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GOVX
this stock
GeoVax Labs, Inc.
|
$1.52M | — | -37.1% | — | 3.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.00B | +15.6% | +46.2% | 29.9 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.88B | +4.3% | +20.8% | 19.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.89B | +578.5% | +4.3% | — | 7.7% |
|
CSLLY
Csl Ltd
|
$66.42B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GOVX | -13.6% | -41.3% | -83.8% | -38.3% | -95.2% |
| SPY | -0.4% | -1.5% | +5.8% | -0.4% | +11.5% |
| vs SPY | -13.1% | -39.8% | -89.6% | -38.0% | -106.6% |